中华肝脏病杂志
中華肝髒病雜誌
중화간장병잡지
CHINESE JOURNAL OF HEPATOLOGY
2009年
9期
691-694
,共4页
郭健文%习东%严伟明%罗小平%宁琴
郭健文%習東%嚴偉明%囉小平%寧琴
곽건문%습동%엄위명%라소평%저금
肝功能衰竭%急性%动物模型%猪纤维介素
肝功能衰竭%急性%動物模型%豬纖維介素
간공능쇠갈%급성%동물모형%저섬유개소
Liver failure%actue%Animal model%Pig fibrinogen-like protein 2
目的 建立一个模拟人类疾病进程的猪急性肝衰竭(ALF)模型,用于ALF治疗药物的临床前安全性评价及疗效评价,检测模型中猪纤维介素(pfg12)的表达情况,为针对fg12的基因治疗提供基础和依据. 方法造模组耳静脉快速注射D-氨基半乳糖盐酸盐,剂量1.2 g/kg;对照组耳静脉快速注射5%的葡萄糖,剂量12 ml/kg.观察两组动物临床表现,肝功能指标和肝组织病理学改变,实时定量PCR检测肝组织中pfg12 mRNA表达,免疫组织化学检测肝组织中pfg12蛋白的表达.采用重复测量数据的方差分析和独立样本t检验进行统计学处理.结果 成功建立了与人在临床表现、肝脏生物化学指标、组织病理学改变相似的猪ALF模型;实时定量PCR检测结果显示造模组猪肝组织中pfg12的mRNA表达水平显著增加,与对照组比较,差异具有统计学意义(t=7.695,P<0.05).免疫组织化学显示造模组猪肝组织中有明显的pfg12蛋白的表达,主要分布在肝细胞坏死区域的肝细胞、炎症浸润细胞、肝血窦内皮细胞及血管内皮细胞,对照组动物肝组织未见pfg12阳性着色.结论 以D-氨基半乳糖盐酸盐诱导的猪ALF模型可用于评价肝衰竭治疗药物的临床前疗效及安全性;pfg12在猪ALF动物模型的肝组织中异常高表达,提示其参与了ALF时肝细胞坏死的发生和发展过程.
目的 建立一箇模擬人類疾病進程的豬急性肝衰竭(ALF)模型,用于ALF治療藥物的臨床前安全性評價及療效評價,檢測模型中豬纖維介素(pfg12)的錶達情況,為針對fg12的基因治療提供基礎和依據. 方法造模組耳靜脈快速註射D-氨基半乳糖鹽痠鹽,劑量1.2 g/kg;對照組耳靜脈快速註射5%的葡萄糖,劑量12 ml/kg.觀察兩組動物臨床錶現,肝功能指標和肝組織病理學改變,實時定量PCR檢測肝組織中pfg12 mRNA錶達,免疫組織化學檢測肝組織中pfg12蛋白的錶達.採用重複測量數據的方差分析和獨立樣本t檢驗進行統計學處理.結果 成功建立瞭與人在臨床錶現、肝髒生物化學指標、組織病理學改變相似的豬ALF模型;實時定量PCR檢測結果顯示造模組豬肝組織中pfg12的mRNA錶達水平顯著增加,與對照組比較,差異具有統計學意義(t=7.695,P<0.05).免疫組織化學顯示造模組豬肝組織中有明顯的pfg12蛋白的錶達,主要分佈在肝細胞壞死區域的肝細胞、炎癥浸潤細胞、肝血竇內皮細胞及血管內皮細胞,對照組動物肝組織未見pfg12暘性著色.結論 以D-氨基半乳糖鹽痠鹽誘導的豬ALF模型可用于評價肝衰竭治療藥物的臨床前療效及安全性;pfg12在豬ALF動物模型的肝組織中異常高錶達,提示其參與瞭ALF時肝細胞壞死的髮生和髮展過程.
목적 건립일개모의인류질병진정적저급성간쇠갈(ALF)모형,용우ALF치료약물적림상전안전성평개급료효평개,검측모형중저섬유개소(pfg12)적표체정황,위침대fg12적기인치료제공기출화의거. 방법조모조이정맥쾌속주사D-안기반유당염산염,제량1.2 g/kg;대조조이정맥쾌속주사5%적포도당,제량12 ml/kg.관찰량조동물림상표현,간공능지표화간조직병이학개변,실시정량PCR검측간조직중pfg12 mRNA표체,면역조직화학검측간조직중pfg12단백적표체.채용중복측량수거적방차분석화독립양본t검험진행통계학처리.결과 성공건립료여인재림상표현、간장생물화학지표、조직병이학개변상사적저ALF모형;실시정량PCR검측결과현시조모조저간조직중pfg12적mRNA표체수평현저증가,여대조조비교,차이구유통계학의의(t=7.695,P<0.05).면역조직화학현시조모조저간조직중유명현적pfg12단백적표체,주요분포재간세포배사구역적간세포、염증침윤세포、간혈두내피세포급혈관내피세포,대조조동물간조직미견pfg12양성착색.결론 이D-안기반유당염산염유도적저ALF모형가용우평개간쇠갈치료약물적림상전료효급안전성;pfg12재저ALF동물모형적간조직중이상고표체,제시기삼여료ALF시간세포배사적발생화발전과정.
Objective To establish a pig model of fulminant hepatic failure for evaluating the preclinical efficacy of drug treatment on severe hepatitis,and to detect the expression of fibrinogen-like protein2(fg12)prothrombinase in the model,so as to provide basis for gene therapy targeting to fg12 for fulminant hepatic failure.Method D-galactosamine hydrochloride was used to induce pig model of fulminant hepatic failure,and the experiment animals were divided into model group(rapid injection of D-galactosamine hydrochloride by ear vein,a dose of 1.2 g/kg)and negative control group(5%Glucose).Clinical,biochemical and pathological changes of animals were observed.The expression of pigs fg12(pfg12)mRNA in liver tissue was detected by real time RT-PCR,the expression of pfg12 protein in liver tissue was detected by immunohistochemistry.Results A pig model of fulminant hepatic failure WaS successfully established using the D-galactose hydrochloride;Real time RT-PCR of liver fg12 mRNA showed that fg12 mRNA expression was increased significantly in liver tissue of fulminant hepatic failure pig model compared with the control group(P=0.0 1 6);Immunohistochemical staining showed that there were fg12 protein expression in liver tissue of fulminant hepatic failure pig model,mainly in the membrane and cytoplasm of hepatocytes,inflammatory cells,liver sinusoidal endothelial cells and vascular endothelial cells of liver cell necrosis region.However,there are no fg12 positive staining on negative control. Conclusions The pig model of fulminant hepatic failure induced by D-galactosamine hydrochloride is similar to human pathological process and can be used to evaluate the pre-clinical efficacy and safety of drug treatment on fulminant hepatic failure. Abnormal expression of pfg12 at both mRNA level and protein level in the liver of fuiminant hepatic failure pig model shows that pfg12 induced coagulation pathway is also involved in the development of fulminant hepatic failure. Gene therapy targeting fg12 genes for fulminant hepatic failure may provide a new means for the treatment of fulminant hepatic failure.